Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kinetozyme-D
- Development stage
- Unknown
- Lead developer
- Systopic Laboratories
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Kinetozyme-D is an oral fixed-dose combination tablet developed by Systopic Laboratories for the management of pain, swelling, and inflammation associated with various musculoskeletal and joint disorders, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as post-operative and post-traumatic recovery. The formulation combines the nonsteroidal anti-inflammatory drug (NSAID) diclofenac with the proteolytic enzymes trypsin, chymotrypsin, and bromelain, and the antioxidant flavonoid rutoside. Diclofenac acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2) to reduce prostaglandin synthesis, thereby providing potent analgesic and anti-inflammatory effects. The proteolytic enzymes trypsin, chymotrypsin, and bromelain work synergistically to break down inflammatory proteins and necrotic debris, improve microcirculation, and facilitate tissue repair. Rutoside strengthens capillaries, reduces vascular permeability to prevent edema, and neutralizes free radicals. Together, these components offer a comprehensive, multi-targeted approach to accelerate healing and relieve pain.
- Brand names
- Kinetozyme-D
- Other names
- bromelain + diclofenac + rutoside + trypsin + chymotrypsinbromelain + diclofenac + rutoside + trypsin-chymotrypsin
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Kinetozyme-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kinetozyme-D.